Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults

Clinical Therapeutics

Volumn 38, Issue 7, 2016, Pages 1674-1685.e1

  Song, Yan ^a   Chang, Ming ^a   Suzuki, Akiyuki ^b   Frost, Robert J A ^a   Kelly, Anne ^a   LaCreta, Frank ^a   Frost, Charles ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b PFIZER INC   (United States)

Author keywords

apixaban; bioavailability; crushed tablet; food effect; formulation; stability

Indexed keywords

ANTIHISTAMINIC AGENT; APIXABAN; CORTICOSTEROID; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; TABLET;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALORIC INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG STABILITY; EVALUATION STUDY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TABLET; BIOAVAILABILITY; DIET RESTRICTION; FOOD DRUG INTERACTION; ORAL DRUG ADMINISTRATION; THERAPEUTIC EQUIVALENCE;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG STABILITY; FACTOR XA INHIBITORS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; PYRAZOLES; PYRIDONES; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 84978286872     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.05.004     Document Type: Article

References (52)

1. 1 Pinto, D.J., Orwat, M.J., Koch, S., et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50 (2007), 5339–5356.
2. 2 Wong, P.C., Crain, E.J., Xin, B., et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, an-ti-throm-bot-ic and antihemostatic studies. J Thromb Haemost 6 (2008), 820–829.
3. 3 Connolly, S.J., Eikelboom, J., Joyner, C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 364 (2011), 806–817.
4. 4 Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
5. 5 Lassen, M.R., Raskob, G.E., Gallus, A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361 (2009), 594–604.
6. 6 Lassen, M.R., Raskob, G.E., Gallus, A., et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375 (2010), 807–815.
7. 7 Lassen, M.R., Gallus, A., Raskob, G.E., et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363 (2010), 2487–2498.
8. 8 Agnelli, G., Buller, H.R., Cohen, A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369 (2013), 799–808.
9. 9 Agnelli, G., Buller, H.R., Cohen, A., et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368 (2013), 699–708.
10. 10 Chang, M., Yu, Z., Shenker, A., et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 1 (2012), 185–186.
11. 11 Frost, C., Yu, Z., Wang, J., Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther, 85(suppl 1), 2009, S34.
12. 12 Frost, C., Nepal, S., Wang, J., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 76 (2013), 776–786.
13. 13 Frost, C.E., Song, Y., Shenker, A., et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet 54 (2015), 651–662.
14. 14 Upreti, V.V., Wang, J., Barrett, Y.C., et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 5 (2013), 59–66.
15. 15 Yamahira, N., Frost, C., Fukase, H., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther 52 (2014), 564–573.
16. 16 Frost, C., Wang, J., Nepal, S., et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75 (2013), 476–487.
17. ® (apixaban) tablets. Prescribing information. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed March 20, 2014.
18. 18 Frost, C., Wang, X., Nepal, S., et al. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects. Clin Pharmacol Drug Dev, 2, 2013, 19 (Abstract 1703161).
19. 19 Raghavan, N., Frost, C.E., Yu, Z., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37 (2009), 74–81.
20. 20 Zhang, D., He, K., Raghavan, N., et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos 37 (2009), 1738–1748.
21. 21 Frost, C., Wang, J., Nepal, S., Apixaban does not affect the pharmacokinetics of digoxin. J Clin Pharmacol, 47, 2007, 1196.
22. 22 Frost, C.E., Byon, W., Song, Y., et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 79 (2015), 838–846.
23. 23 Frost, C., Shenker, A., Gandhi, M.D., et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol 78 (2014), 877–885.
24. 24 Upreti, V.V., Song, Y., Wang, J., et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol 5 (2013), 59–66.
25. 25 Vakkalagadda, B., Frost, C., Wang, J., et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa [abstract]. J Clin Pharmacol 49 (2009), 1091–1130.
26. 26 Wang, L., Zhang, D., Raghavan, N., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 38 (2010), 448–458.
27. 27 Zhang, D., He, K., Herbst, J., et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos 41 (2013), 827–835.
28. 28 Lindgren, S., Janzon, L., Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia 6 (1991), 187–192.
29. 29 Kjellen, G., Tibbling, L., Manometric oesophageal function, acid perfusion test and symptomatology in a 55-year-old general population. Clin Physiol 1 (1981), 405–415.
30. 30 Bloem, B.R., Lagaay, A.M., van, B.W., et al. Prevalence of subjective dysphagia in community residents aged over 87. BMJ 300 (1990), 721–722.
31. 31 Kawashima, K., Motohashi, Y., Fujishima, I., Prevalence of dysphagia among community-dwelling elderly individuals as estimated using a questionnaire for dysphagia screening. Dysphagia 19 (2004), 266–271.
32. 32 Eslick, G.D., Talley, N.J., Dysphagia: epidemiology, risk factors and impact on quality of life–a population-based study. Aliment Pharmacol Ther 27 (2008), 971–979.
33. 33 Schiele, J.T., Quinzler, R., Klimm, H.D., et al. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol 69 (2013), 937–948.
34. 34 Bekele, E., Thornburg, C.D., Brandow, A.M., et al. Do difficulties in swallowing medication impede the use of hydroxyurea in children?. Pediatr Blood Cancer 61 (2014), 1536–1539.
35. 35 Marquis, J., Schneider, M.P., Payot, V., et al. Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. Int J Clin Pharm 35 (2013), 1130–1136.
36. 36 Kelly, J., Wright, D., Wood, J., Medicine administration errors in patients with dysphagia in secondary care: a multi-centre observational study. J Adv Nurs 67 (2011), 2615–2627.
37. ® (dabigatran etexilate mesylate) capsules. Prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022512s017lbl.pdf. Accessed March 3, 2015.
38. 38 Yu, L.X., Amidon, G.L., Polli, J.E., et al. Biopharmaceutics Classification System: the scientific basis for biowaiver extensions. Pharm Res 19 (2002), 921–925.
39. 39 Wong, P.C., Pinto, D.J., Zhang, D., Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 31 (2011), 478–492.
40. ® (warfarin sodium) tablets. Prescribing information. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed March 3, 2015.
41. 41 Kubitza, D., Becka, M., Zuehlsdorf, M., et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46 (2006), 549–558.
42. ® (rivaroxaban) tablets. Prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf. Accessed February 6, 2015.
43. 43 Pursley, J., Shen, J.X., Schuster, A., et al. LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 6 (2014), 2071–2082.
44. 44 Diletti, E., Hauschke, D., Steinijans, V.W., Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 29 (1991), 1–8.
45. 45 Song, Y., Wang, X., Perlstein, I., et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther 37 (2015), 1703–1712.
46. 46 Dresser, G.K., Bailey, D.G., Leake, B.F., et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71 (2002), 11–20.
47. 47 Breedveld, P., Beijnen, J.H., Schellens, J.H., Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27 (2006), 17–24.
48. 48 Gu, C.H., Li, H., Levons, J., et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res 24 (2007), 1118–1130.
49. 49 Doroshyenko, O., Jetter, A., Odenthal, K.P., et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 44 (2005), 701–720.
50. 50 Radwan, A., Amidon, G.L., Langguth, P., Mechanistic investigation of food effect on disintegration and dissolution of BCS class III compound solid formulations: the importance of viscosity. Biopharm Drug Dispos 33 (2012), 403–416.
51. 51 Martinez, M.N., Amidon, G.L., A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42 (2002), 620–643.
52. 52 Penrod, L.E., Allen, J.B., Cabacungan, L.R., Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil 82 (2001), 1270–1273.